<Page>

                                                                    Exhibit 99.1


                                                          Filed Pursuant to
                                                          Rule 424(b)(3) and (c)
                                                          File No. 333-98927

                 PROSPECTUS SUPPLEMENT DATED SEPTEMBER 23, 2002
                     TO PROSPECTUS DATED SEPTEMBER 17, 2002

         After the close of business on September 17, 2002, Harvard Bioscience,
Inc. announced new financial guidance for the fiscal year ended December 31,
2002. In the announcement, Harvard Bioscience revised downward its previously
announced guidance due to the continued slower than expected adoption of its
COPAS (TM) technology and unexpected weakness in its international business in
the third quarter.

         Harvard Bioscience common stock is traded on the Nasdaq National Market
under the trading symbol "HBIO" and on September 20, 2002, the closing price of
Harvard Bioscience common stock was $2.82 per share. Consequently, based on this
price, applying an assumed conversion ratio as of September 20, 2002 of 0.1016
of a share of Harvard Bioscience common stock and $0.2858 in cash for each share
of Genomic Solutions common stock, the equivalent price per share of Genomic
Solutions common stock on September 20, 2002 was $0.5723. This amount is an
estimate based on the number of outstanding shares of Genomic Solutions common
stock on September 20, 2002, and assuming that all in-the-money options to
purchase Genomic Solutions common stock outstanding on September 20, 2002 are
exercised prior to the merger and may change at the completion of the merger as
a result of changes in the number of shares of Genomic Solutions common stock
outstanding due to, among other things, actual stock option exercises and
purchases under the Genomic Solutions employee stock purchase plan.

         Because the market price of Harvard Bioscience common stock may
increase or decrease before the completion of the merger, you are urged to
obtain current market quotations.

         You are encouraged to read and consider carefully the discussion in the
section entitled "Risk Factors" beginning on page 21 of the proxy statement and
prospectus to which this supplement relates.


NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THE MERGER OR THE SHARES OF HARVARD
BIOSCIENCE COMMON STOCK TO BE ISSUED IN THE MERGER, OR DETERMINED IF THE PROXY
STATEMENT AND PROSPECTUS IS ACCURATE OR ADEQUATE. ANY REPRESENTATION TO THE
CONTRARY IS UNLAWFUL.